Ebrahimi Seyyed Reza Sadat, Enamzadeh Elgar, Babaei Hossein
Drug Applied Research Center, Department of Pharmacology and Toxicology, School of Pharmacy, Tabriz University of Medical Sciences, Tabriz 51656-65811, Iran.
Student Research Committee, Tabriz University of Medical Sciences, Tabriz 51664-14766, Iran.
Curr Clin Pharmacol. 2017;12(4):223-230. doi: 10.2174/1574884713666180223121828.
Polidocanol is approved for its competence in the treatment of varicose veins and spider veins; however, unfortunately, many of its off-label uses are still underappreciated.
Lack of an appropriate comprehensive review for off-label uses of this medication troubles physicians about making evidence-based decisions on prescribing it for its various outstanding off-label uses. This article attempts to provide physicians with the latest information concerning successful and unsuccessful use of polidocanol as an alternative treatment for esophageal and gastric varices, tendinopathy and epicondylitis, vascular malformations, varicocele, hydrocele and spermatocele, aneurysmal bone cysts, itching, management of gastrointestinal bleeding, simple renal cysts, reducing the incidence and severity of radio-induced dermatitis and hemorrhoids.
The two databases of MEDLINE and Cochrane Library were searched for all human English studies, published in January 2006 to November 2017, which contained the keyword of "polidocanol" or its alternative MeSH terms.
Our search identified a total number of 597 articles. Those articles that were only discussing the approved uses of polidocanol were excluded and the remaining 116 articles were reviewed. Eleven major and 30 minor off-label uses were found within included studies.
Numerous successful administrations of this drug in a variety of clinical conditions lead to promising perspectives toward it. Sclerotherapy with polidocanol as a minimal-invasive method (having similar outcomes like the prevalent surgeries) may reduce the rate of complications. Furthermore, for determining the most appropriate method and dosage, randomized clinical trials are needed, confirming and providing more clear instructions for different conditions.
聚多卡醇因其在治疗静脉曲张和蜘蛛状静脉方面的能力而被批准使用；然而，不幸的是，它的许多非标签用途仍未得到充分认识。
缺乏对该药物非标签用途的适当全面综述，这给医生在基于证据决定将其用于各种突出的非标签用途时带来困扰。本文试图为医生提供有关聚多卡醇作为食管和胃静脉曲张、肌腱病和肱骨外上髁炎、血管畸形、精索静脉曲张、鞘膜积液和精液囊肿、动脉瘤样骨囊肿、瘙痒、胃肠道出血管理、单纯性肾囊肿、降低放射性皮炎和痔疮的发生率和严重程度的替代治疗的成功和不成功使用的最新信息。
检索MEDLINE和Cochrane图书馆这两个数据库，查找2006年1月至2017年11月发表的所有英文人体研究，这些研究包含关键词“聚多卡醇”或其替代医学主题词。
我们的检索共识别出597篇文章。排除那些仅讨论聚多卡醇批准用途的文章，对其余116篇文章进行了综述。在纳入的研究中发现了11种主要和30种次要的非标签用途。
该药物在多种临床情况下的大量成功应用为其带来了有前景的前景。以聚多卡醇进行硬化疗法作为一种微创方法（具有与普遍手术相似的结果）可能会降低并发症发生率。此外，为了确定最合适的方法和剂量，需要进行随机临床试验，为不同情况确认并提供更明确的指导。
